Serum IL-6 and Procalcitonin Are Two Promising Novel Biomarkers for Evaluating the Severity of COVID-19 Patients.

Jinsong Tang,Jingtao Lin,Erying Zhang,Mengru Zhong,Yong Luo,Yong Fu,Yewei Yang
DOI: https://doi.org/10.1097/md.0000000000026131
IF: 1.6
2021-01-01
Medicine
Abstract:To evaluate the development of coronavirus disease 2019 (COVID-19), the roles of interleukin 6 (IL-6) and procalcitonin (PCT) were assessed to diagnose severe COVID-19. Between January and February 2020, 100 consecutive patients with confirmed COVID-19 were included and divided into common (n = 56), severe (n = 28), and critical (n = 16) groups. IL-6 and PCT levels were assayed and compared among groups. IL-6 levels were significantly different among groups (common, 23.93 +/- 9.64 pg/mL; severe, 69.22 +/- 22.98 pg/mL; critical, 160.34 +/- 26.15 pg/mL; P < .05), and there was also a significant difference in the levels of PCT among groups (common, 0.23 +/- 0.13 ng/mL; severe, 0.38 +/- 0.16 ng/mL; critical, 0.73 +/- 0.36 ng/mL; P < .05). Further analysis showed that patients in the critical group had the highest levels of IL-6 and PCT, and those in the common group had the lowest levels (all P < .05). IL-6 and PCT are associated with the severity of COVID-19, and thus have potential value in the diagnosis of COVID-19.
What problem does this paper attempt to address?